Project Grant R01CA291244
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$1.3M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is providing $1,337,014 over approximately 5 years starting September 1, 2024 to investigate the mechanisms by which Kaposi's Sarcoma-Associated Herpesvirus (KSHV) manipulates cellular metabolism to facilitate viral replication and tumor growth. The key research objectives are to: 1) Determine how KSHV's viral cyclin protein...
This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...
This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
This Project Grant award of $877,104 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the interactions between Kaposi's sarcoma-associated herpesvirus (KSHV), mononuclear phagocytes, and B cells, and how KSHV establishes long-term latency in B cells. The research, conducted by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will use computational...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), aims to develop and test novel vaccine platforms against Kaposi's Sarcoma-Associated Herpesvirus (KSHV) infection. The key objectives are: 1) to test three different KSHV vaccine platforms, and 2) to develop a chimeric murine herpesvirus 68 (MHV68) expressing KSHV glycoproteins as a surrogate challenge virus for evaluating KSHV vaccine efficacy in a mouse...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $476,754 to Barnard College to study the molecular mechanisms of Kaposi sarcoma, a cancer associated with the Kaposi sarcoma-associated herpesvirus (KSHV). The project aims to identify virus-associated host enhancers and regulated genes, as well as host super-enhancers, in actual Kaposi sarcoma tissue samples. This research will be conducted by undergraduate students at Barnard College,...
This federal Project Grant award of $185,513, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to develop O'PROTAC-based degraders that specifically target the KSHV-encoded LANA oncoprotein to interfere with the survival of Kaposi's sarcoma-associated herpesvirus (KSHV)-positive tumor cells. The award, with a project period from Nov 2024 to Oct 2026, is funding research at the University of Arkansas for Medical...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, supports research to decipher the immune evasion mechanisms of cancers harboring mutations in the IDH1 gene. The $196,029 award, effective April 1, 2025 through March 31, 2028, will fund the University of Massachusetts Medical School's investigation into two key processes that contribute to the immunosuppressive tumor microenvironment in IDH1-mutant cancers: 1) the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $634,981 to the University of Pittsburgh to investigate the role of Merkel cell polyomavirus (MCV) small T antigen in persistent viral infection. The research aims to: 1) Define the MCV early and late promoter sequences, 2) Investigate the impact of the small T antigen on viral chromatin and epigenetic...